BTIG reaffirms Buy on Lucid Diagnostics with $2.50 target
BTIG kept its Buy rating on Lucid Diagnostics shares with a $2.50 price target, implying 662.9% upside from the October 22 close.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing Benzinga data, BTIG reiterated its Buy rating on Lucid Diagnostics shares and kept a $2.50 price target. The target implies a 662.9% gain from the October 22 close of $0.33.
The analyst note points to Lucid receiving Medicare payments for its EsoGuard test. BTIG expects this to significantly boost revenue growth, as it opens the way to coverage from commercial payors and wider market presence. The analysts also highlighted a recent $15 million financing that strengthens the balance sheet and lets the company expand commercial operations and its sales force.
why it matters
For a stock trading around one dollar, reimbursement news matters because it shifts revenue expectations. Investors still need to weigh the risk themselves, since a single analyst target is not a reliable guide on its own.
tags
instruments
sources
- BTIG reiterates Buy rating on Lucid Diagnostics, $2.50 price target — TradingView, 23 October 2026 at 09:56 UTC
- Lucid Diagnostics Price Target Maintained With a $2.50/Share by BTIG — Dow Jones Newswires, 23 October 2026 at 10:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗